Cytokinetics, Incorporated (CYTK) Shareholders’ equity 2016–2025
Cytokinetics, Incorporated (CYTK) shareholders’ equity at each fiscal year-end, per SEC filings.
-$659.6MFY2025 · since FY2016: $94.4M → -$659.6M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$659.6M | -387.3% |
| FY2024 | -$135.4M | +65.0% |
| FY2023 | -$386.3M | -258.0% |
| FY2022 | -$107.9M | -144.2% |
| FY2021 | $243.9M | +115.1% |
| FY2020 | $113.4M | +1136.7% |
| FY2019 | -$10.9M | -142.2% |
| FY2018 | $25.9M | -76.4% |
| FY2017 | $109.8M | +16.4% |
| FY2016 | $94.4M | — |
Source: SEC XBRL filings · For reference only · Not investment advice